drugset / Trial / NCT01146119

Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001)

NCT01146119

Phase 2 Completed 200 enrolled BiondVax Pharmaceuticals ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a multi-center, randomized, two stage, double-blind, placebo-controlled administration study comprising 200 healthy participants.

Timeline

Start
2010-07
Primary completion
2011-05
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Multimeric-001 Vaccine 500 ug Intramuscular
Comparator TIV Vaccine 15 % Intramuscular
Comparator TIV Vaccine 50 % Intramuscular

Indications